![Einat Galamidi](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 8 440 $ al 31/05/2026
Einat Galamidi currently works at Enlivex Therapeutics Ltd., as Chief Medical Officer from 2025.
Dr. Galamidi also formerly worked at Gamida Cell Ltd., as Vice President-Clinical Development.
Dr. Galamidi received her doctorate degree from The Hebrew University of Jerusalem.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ENLIVEX LTD. 0 % | 18/03/2026 | 10.420 ( 0 % ) | 8 440 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ENLIVEX | Director Técnico/Científico/I+D | 01/02/2025 |
| Empresas | Cargo | Fin |
|---|---|---|
| GAMIDA CELL LTD. | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
| Empresas privadas | 3 |
|---|---|
The Hebrew University of Jerusalem
 The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gamida Cell Ltd.
 Gamida Cell Ltd. Pharmaceuticals: MajorHealth Technology Engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases | Health Technology |
Enlivex Therapeutics Ltd.
 Enlivex Therapeutics Ltd. BiotechnologyHealth Technology Develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
Elige MarketScreener 
